This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The annual risk of TB was derived from a general review. The efficacy of treatment of latent TB infection was derived from a clinical trial. The age-specific risks of death were derived from a published cost-effectiveness analysis.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two primary studies and one review were included in the review.
Methods of combining primary studies
The results of the primary studies were not combined since their primary outcomes were different.
Investigation of differences between primary studies
Not relevant since the studies included in the review evaluated different primary outcomes.
Results of the review
The reduction in risk of TB was: 69% after 2 months of R-Z therapy or 6 months of IS therapy;
20% after 1 month of R-Z therapy or 3 to 5 months of IS therapy; and 0% after less than 1 month of R-Z therapy or less than 3 months of IS therapy.
The annual risk of TB without treatment of latent infection was 0.27.
The relative risk of death due to TB was 3.9 for patients aged 35 -44 years old, 7.4 for patients aged 45 -64 years old, and 16.8 for patients aged 65 years or older.
The annual, age-specific all-cause risk of death was not reported.
Methods used to derive estimates of effectiveness
The study was also based on authors' assumptions.
Estimates of effectiveness and key assumptions
Since there were no studies evaluating the efficacy of R-Z therapy in adults without HIV infection, it was assumed that its efficacy was equal to that of IS administered to patients without HIV infection. months were $273 per patient treated.
The costs of treating adverse events were included in the analysis. The costs were estimated over a patient lifetime (up to 99 years of age or death) and were discounted at 3% annually.
Synthesis of costs and benefits
IS was the dominant option compared with R-Z, as it was less costly and equally effective. IS was also the dominant option compared with no treatment, as it was less costly and more effective. R-Z was more effective than no treatment, but at an incremental cost of $2,492 per additional TB case prevented.
Sensitivity analyses showed that, assuming equal efficacy between the two regimens, there was no threshold completion rate for R-Z at which the two treatments would be of equal net cost.
The results were insensitive to changes in R-Z completion rates when the IS completion rate remained at 68%. In contrast, at an IS completion rate of 36% or less (and 68% R-Z completion rate), R-Z would become cost-saving in comparison with IS. R-Z would also be cost-saving relative to IS if its efficacy rose to 90% and its completion rate was 80% or more. In terms of rates of IS-resistant infections, these would have to increase at 42% in order for the two treatments to incur equal total costs per patient. The results were not sensitive to a 9-month duration of IS treatment, or to the routine testing of liver enzyme levels in patients receiving IS.
